Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bradykinin antagonists: discovery and development.

John M Stewart1

  • 1Department of Biochemistry, University of Colorado Medical School, Denver, CO 80262, USA. john.stewart@uchsc.edu

Peptides
|May 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALK+ Large B-Cell Lymphoma With Novel ZNF296::ALK: A Morphologic Mimic of ALK+ Anaplastic Large Cell Lymphoma.

American journal of hematology·2025
Same author

Extramedullary Hematopoiesis in Serous Cavity Fluids: A Closer Look at This Rare Phenomenon With Diagnostic Pitfalls and Prognostic Significance.

Diagnostic cytopathology·2024
Same author

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features.

Frontiers in oncology·2024
Same author

Cytopathology assistance for optimizing interventional diagnostic procedures.

Seminars in diagnostic pathology·2022
Same author

Primary Pancreatic Lymphoma Evaluated by Fine-Needle Aspiration.

American journal of clinical pathology·2022
Same author

Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB.

Cancer cytopathology·2021
Same journal

Potential role of intelectin-1 in the regulation of feeding of goldfish (Carassius auratus).

Peptides·2026
Same journal

Cocaine- and amphetamine-regulated transcript (CART) peptides: Neuroanatomical distribution and functional implications in the mammalian central nervous system.

Peptides·2026
Same journal

P1642-1, a novel pancreatic polypeptide analogue, ameliorates cognitive impairment in 5 ×FAD mice and is associated with enhanced PINK1/Parkin-related mitophagy.

Peptides·2026
Same journal

Structure-based rational design of high-affinity JAZF1 variants peptides to target the testicular orphan nuclear receptor 4 and pro-opiomelanocortin axis in Cushing's disease.

Peptides·2026
Same journal

[Gly<sup>2</sup>]-GLP-2(1-5): An ultra-short GLP-2 peptide for intestinal mucosal protection in inflammatory bowel disease.

Peptides·2026
Same journal

The role of Kiss1 neurons in regulating metabolism and energy balance.

Peptides·2026
See all related articles

Scientists developed practical bradykinin antagonists, crucial for understanding inflammation and pain. Key modifications led to potent, stable, and orally available peptides, advancing therapeutic potential.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Bradykinin is implicated in inflammatory processes and pain signaling.
  • Early research suggested bradykinin's role, necessitating targeted antagonists.
  • The need for effective bradykinin antagonists was recognized in the early 1980s.

Purpose of the Study:

  • To detail the discovery and development of practical bradykinin antagonists.
  • To highlight key structural modifications leading to improved antagonist properties.
  • To review the progression from initial antagonists to modern, clinically relevant compounds.

Main Methods:

  • Chemical synthesis and modification of peptide structures.
  • Introduction of D-aromatic amino acids at specific residue positions (e.g., position 7).

Related Experiment Videos

  • Assessment of antagonist potency, stability against enzymatic degradation, and oral bioavailability.

    • Main Results:

    • Discovery of practical bradykinin antagonists in 1984.
    • Identification of proline replacement at position 7 with a D-aromatic amino acid as a key modification.
    • Development of highly stable, orally available peptide antagonists used in clinical trials.
    • Successful development of non-peptide bradykinin antagonists.

    Conclusions:

    • Strategic modifications, particularly proline substitution, are critical for creating effective bradykinin antagonists.
    • Advanced bradykinin antagonists exhibit enhanced stability and oral availability, suitable for clinical applications.
    • The development of both peptide and non-peptide antagonists offers diverse therapeutic strategies for bradykinin-mediated conditions.